Study of TTX-MC138 in Subjects With Advanced Solid Tumors

计划入组 16 人 · 首次发布于 2024 年 2 月 15 日

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

计划入组 240 人 · 首次发布于 2020 年 7 月 24 日

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

计划入组 56 人 · 首次发布于 2019 年 3 月 21 日

TTX-MC138

TTX-330

TTX-334

European Thoracic Oncology Platform

Switzerland

Biodexa Pharmaceuticals

Canada

Generation Bio

United States

TransCode Therapeutics Publishes Breakthrough RIG-I Agonist Study Enabling Tumor-Selective Cancer Immunotherapy

TransCode Therapeutics Secures $10 Million Funding to Advance RNA Cancer Therapy Clinical Trials

TransCode Therapeutics Advances RNA Oncology Pipeline Targeting Metastatic Cancer with Novel Delivery Platform